|By PR Newswire||
|April 3, 2014 07:00 AM EDT||
EAST HANOVER, N.J., April 3, 2014 /PRNewswire/ -- Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research (AACR), April 5-9, 2014 in San Diego, CA. The AACR annual meeting highlights basic, translational and clinical discoveries in oncology. The investigational compounds featured in these Novartis studies are directed at multiple molecular targets and pathways. Currently Novartis Oncology is exploring more than 30 targets involved in cancer1.
"Our research approach is driven by an understanding of cancers on a genomic level and developing therapies directed at those targets," said Alessandro Riva, President, Novartis Oncology ad interim and Global Head, Oncology Development and Medical Affairs. "The AACR presentations demonstrate the depth and breadth of our pipeline, which allows us to test various combinations at an early stage to target different pathways and mutations involved in cancer."
Among the data being presented are single agent and combination studies with key investigational compounds in the Novartis Oncology breast cancer development program, including an early phase study of the CDK4/6 inhibitor LEE011 and PI3K inhibitors BKM120 and BYL719. LEE011 and BKM120 are currently in Phase III and BYL719 is in Phase I trials for the treatment of advanced breast cancer.
In addition, preclinical data on ALK-inhibitor LDK378 (ceritinib) in ALK-positive non-small cell lung cancer (NSCLC) will be presented at the meeting. LDK378 was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) in 2013 and is currently under review by the FDA.
Early data will be presented on three additional investigational compounds including BGJ398, a highly specific fibroblast growth factor receptor (FGFR) inhibitor that Novartis is exploring in a variety of FGFR-driven solid tumors. A Phase I study of BGJ398 provides the first clinical evidence of activity against cancers that are driven by dysregulation of the FGFR pathway. In addition, the first data on CGM097, a selective p53-Mdm2 inhibitor currently under evaluation in Phase I trials in patients with p53 wild type tumors, and EGF816, a mutant-selective third generation EGFR inhibitor that is entering Phase I trials, will be presented.
More than 50 abstracts involving Novartis investigational compounds will be presented at AACR, including:
- In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer (Abstract #4756; April 8, 4:05 p.m.)
- Loss of PTEN leads to clinical resistance to the PI3K inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure (Abstract #LB327; April 8, 3:50 p.m.; this abstract will also be presented as part of the official AACR press briefing on April 8 at 7:30 a.m.)
- The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer (Abstract #957; April 6, 4:05 p.m.)
- Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma (Abstract #1000; April 6, 4:35 p.m.)
- The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models (Abstract #2929; April 7, 4:35 p.m.)
- Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors (Abstract #CT326; April 8, 10:50 a.m.; this abstract will also be presented as part of the official AACR press briefing on April 8 at 7:30 a.m.)
- Pre-clinical characterization and clinical development of NVP-CGM097, a highly selective and optimized small-molecule inhibitor of p53-Mdm2 protein-protein interaction (Abstract #ED37-01; April 5, 3:15 p.m.)
- Discovery of NVP-CGM097 as a novel Mdm2 inhibitor (Abstract #DDT01-01; April 6, 1:00 p.m.)
- A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models (Abstract #2909; April 7, 3:00 p.m.)
- The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma (Abstract #5466; April 9, 8:00 a.m.)
- EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC (Abstract #1733; April 7, 2014, 8:00 a.m.)
- In vitro characterization of EGF816, a third-generation mutant-selective EGFR inhibitor (Abstract #1734; April 7, 8:00 a.m.)
About LEE011, BKM120, BYL719, LDK378, BGJ398, CGM097, LGX818 and EGF816
Because these are investigational compounds, the safety and efficacy profiles of LEE011, BKM120, BYL719, LDK378, BGJ398, CGM097, LGX818 and EGF816 have not yet been established. Access to these investigational compounds is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the treatments. Because of the uncertainty of clinical trials, there is no guarantee that LEE011, BKM120, BYL719, LDK378, BGJ398, CGM097, LGX818 and EGF816 will ever be commercially available anywhere in the world. The prefix NVP before a code name is the same compound as the code name alone.
LEE011 was discovered as part of a drug discovery collaboration between the Novartis Institutes for BioMedical Research and Astex Pharmaceuticals.
The BYL719 and BGJ398 abstracts will be presented as part of an official AACR press briefing on Tuesday April 8 at 7:30 a.m. PT in room 15B of the San Diego Convention Center. Reporters unable to attend in person can dial in by calling 1 (866) 297-6395 (US/Canada) or 1 (847) 944-7317 (International), confirmation code: 36855822.
The foregoing release contains forward-looking statements that can be identified by words such as "pipeline," "investigational," "will," "exploring," "being presented," "leads to," "predicts," "yet," "designed," "potential," or similar terms, or by express or implied discussions regarding potential marketing authorizations for LEE011, BKM120, BYL719, LDK378, BGJ398, CGM097, LGX818, EGF816 or any other Novartis compounds to be presented at the AACR annual meeting, or regarding potential future revenues from such compounds. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of such compounds will be approved for sale in any market where such compounds have been submitted, or will be submitted or approved for sale in any additional markets, or at any particular time. Nor can there be any guarantee that such compounds will be commercially successful in the future. In particular, management's expectations regarding such compounds could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative medicines aimed at improving patients' lives. We offer a broad range of medicines for cancer, cardiovascular disease, endocrine disease, inflammatory disease, infectious disease, neurological disease, organ transplantation, psychiatric disease, respiratory disease and skin conditions. The company's mission is to improve people's lives by pioneering novel healthcare solutions.
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
- American Association of Cancer Research. AACR 2014 Annual Meeting Program. Available at: http://www.abstractsonline.com/plan/start.aspx?mkey=%7B6FFE1446-A164-476A-92E7-C26446874D93%7D
Novartis Media Relations
Novartis Media Relations
+1 212 830 2465 (direct)
+1 862 778 2836
+1 862 579 8456 (mobile)
+1 862 210 5328
e-mail: [email protected]
SOURCE Novartis Pharmaceuticals Corporation
In a world of ever-accelerating business cycles and fast-changing client expectations, the cloud increasingly serves as a growth engine and a path to new business models. Dynamic clouds enable businesses to continuously reinvent themselves, adapting their business processes, their service and software delivery and their operations to achieve speed-to-market and quick response to customer feedback. As the cloud evolves, the industry has multiple competing cloud technologies, offering on-premises ...
May. 6, 2015 12:00 AM EDT Reads: 3,126
SYS-CON Media announced today that Blue Box as launched a popular blog feed on Cloud Computing Journal. Cloud Computing Journal aims to help open the eyes of Enterprise IT professionals to the economics and strategies that utility/cloud computing provides. Blue Box Cloud gives you unequaled agility, without the burden of designing, deploying and managing your own infrastructure. It’s the right choice when public cloud just won’t do. Blue Box Cloud is a managed Private Cloud as a Service (...
May. 6, 2015 12:00 AM EDT Reads: 1,922
Artifactory binary repository management system. As one of the most widely used binary repositories and the only repository that offers a high availability clustered solution, the integration with Artifactory helps customers easily adopt CA Release Automation to optimize their entire software development lifecycle. “Artifactory is a standard maker at the continuous-integration domain and provides the user a powerful repository experience with the freedom to choose his own tools set and ecosyste...
May. 5, 2015 07:45 PM EDT Reads: 478
This talk focuses on the application of DevOps fundamentals to include network infrastructure. It draws from real deployment case studies on the extension of today's paradigms to address the challenges of the network infrastructures' ability to seamlessly and cohesively integrate into agile workflows. In this session at DevOps Summit, Arista Networks will focus on configuration management using automation with a nod to future work necessary to include telemetry and ephemeral state information....
May. 5, 2015 04:45 PM EDT Reads: 1,129
Avnet, Inc. has announced that it ranked No. 4 on the InformationWeek Elite 100 – a list of the top business technology innovators in the U.S. Avnet was recognized for the development of an innovative cloud-based training system that serves as the foundation for Avnet Academy – the company’s education and training organization focused on technical training around top IT vendor technologies. The development of this system allowed Avnet to quickly expand its IT-related training capabilities around...
May. 5, 2015 04:15 PM EDT Reads: 939
SYS-CON Events announced today that dcVAST, a leader in IT infrastructure management, support service and cloud service, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. dcVAST provides cutting-edge IT services and IT infrastructure management services. dcVAST builds robust systems that are simple, secure and serviceable. dcVAST’s IT infrastructure support and IT services expertise can help companies r...
May. 5, 2015 04:02 PM EDT Reads: 615
DevOps Summit, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developmen...
May. 5, 2015 03:45 PM EDT Reads: 900
While Docker continues to be the darling of startups, enterprises and IT innovators around the world, networking continues to be a real mess. Indeed, managing the interaction between Docker containers and networks has always been fraught with complications. Without automation in networking, the vision of running Docker at scale and letting IT run the same apps unchanged on the laptop and in the data center or for any cloud cannot be realized.
May. 5, 2015 03:30 PM EDT Reads: 933
SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Isomorphic Software is the global leader in high-end, web-based business applications. We develop, market, and support the SmartClient & Smart GWT HTML5/Ajax platform, combining the productivity and performance of traditional desktop software ...
May. 5, 2015 03:00 PM EDT Reads: 840
The OnPage SOAP API provides programmatic access to OnPage messaging services. Typical applications include sending messages to individual OnPage users or groups and receiving tracking information for messages such as delivery and read timestamps or reply information. The API is based on open standards known collectively as "Web Services," which includes the Simple Object Access Protocol (SOAP), Web Services Definition Language (WSDL), and the XML Schema Definition language (XSD).
May. 5, 2015 02:37 PM EDT Reads: 351
SYS-CON Events announced today the DevOps Foundation Certification Course, being held June ?, 2015, in conjunction with DevOps Summit and 16th Cloud Expo at the Javits Center in New York City, NY. This sixteen (16) hour course provides an introduction to DevOps – the cultural and professional movement that stresses communication, collaboration, integration and automation in order to improve the flow of work between software developers and IT operations professionals. Improved workflows will res...
May. 5, 2015 02:30 PM EDT Reads: 3,397
Docker is becoming very popular--we are seeing every major private and public cloud vendor racing to adopt it. It promises portability and interoperability, and is quickly becoming the currency of the Cloud. In his session at DevOps Summit, Bart Copeland, CEO of ActiveState, discussed why Docker is so important to the future of the cloud, but will also take a step back and show that Docker is actually only one piece of the puzzle. Copeland will outline the bigger picture of where Docker fits a...
May. 5, 2015 02:15 PM EDT Reads: 5,327
Ayla Networks, whose agile Internet of Things (IoT) platform makes it easy for manufacturers to deliver secure, connected products, today announced it has been included in the list of "Cool Vendors" in the Internet of Things report by Gartner, Inc. “Gartner knows how important it is that manufacturers of all kinds of products have the right IoT solution to help turn their products into connected ‘things,’” said David Friedman, CEO and co-founder of Ayla Networks. “The market for Ayla’s IoT pla...
May. 5, 2015 02:00 PM EDT Reads: 508
A new definition of Big Data & the practical applications of the defined components & associated technical architecture models This presentation introduces a new definition of Big Data, along with the practical applications of the defined components and associated technical architecture models. In his session at Big Data Expo, Tony Shan will start with looking into the concept of Big Data and tracing back the first definition by Doug Laney, and then he will dive deep into the description of 3V...
May. 5, 2015 02:00 PM EDT Reads: 1,141
SYS-CON Events announced today that CenturyLink, Inc., a leader in the network services market, has been named “Platinum Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. CenturyLink is the third largest telecommunications company in the United States and is recognized as a leader in the network services market by technology industry analyst firms. The company is a global leader in cloud infrastructure and ...
May. 5, 2015 01:15 PM EDT Reads: 1,286